Gliatech has reported that Adcon-L (anti-adhesion barrier gel) has beencleared for marketing by the US Food and Drug Administration for the inhibition of postsurgical scarring and adhesions following lumbar surgery. Late last year, an FDA advisory panel unanimously voted to recommend approval of the product (Marketletter December 22, 1997).
Adcon-L is a carbohydrate polymer gel which is applied to the wound during lumbar surgery and is designed to block the formation of excess scar tissue and prevent adhesions between the spinal cord and nerve roots and the surrounding muscle and bone.
Although the FDA committee recommended Adcon-L for approval, it said it was skeptical about the product's ability to reduce postoperative pain. Despite this, the agency has approved the following labeling for the product: that Adcon-L significantly reduces postsurgical scarring and adhesions; that it improves patient outcome and reduces activity-related pain compared to the control group; and that it has no significant adverse events attributed to its use.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze